ANALISI STATISTICA

Le differenze fra gruppi sono state analizzate con il t-test di Student usando il software PRISM (GraphPad, San Diego, CA). Un valore di p≤0,05 è stato considerato statisticamente significativo.

BIBLIOGRAFIA

~ 51 ~

BIBLIOGRAFIA

Alfano, D., Gorrasi, A., Li Santi, A., Ricci, P., Montuori, N., Selleri, C.,

Ragno, P. (2015). Urokinase receptor and CXCR4 are regulated by common

miRNA in leukaemia cells. J Cell Mol Med., 19(9):2262-72.

Alfano, D., Franco, P., Vocca, I., Gambi, N., Pisa, V., Mancini, A.,

Caputi, M., Carriero, M., Iaccarino, I., Stoppelli, M. (2005). The urokinase

plasminogen activator and its receptor: role in cell growth and apoptosis.

Thromb Haemost., 93(2):205-11.

Alfano, D., Ragno, P., Stoppelli, M., Ridley, A. (2012). RhoB regulates

uPAR signalling . J Cell Sci., 125(Pt 10):2369-80 .

Ambros, V., Lee, R., Lavanway, A., Williams, P., Jewell, D. (2003).

miRNA and other tiny endogenous RNAs in C. elegans. Curr Biol.,

13(10):807-18.

Baranwal, S., Alahari, S. (2009). miRNA control of tumor cell invasion

and metastasis. Int J Cancer., 126(6):1283-90.

Bartel, D. (2004). MiRNA: genomics, biogenesis, mechanism, and

function. Cell., 116(2):281-97.

Behrendt, N., Rønne, E., Danø, K. (1995). The structure and function

of the urokinase receptor, a membrane protein governing plasminogen

activation on the cell surface. Biol Chem Hoppe Seyler, 376(5):269-79.

Béné, M., Castoldi, G., Knapp, W., Rigolin, G., Escribano, L., Lemez,

P., Ludwig, W., Matutes, E., Orfao, A., Lanza, F., Van't Veer, M. (2004). CD87

(urokinase-type plasminogen activator receptor), function and pathology in

hematological disorders: a review. Leukemia, 18(3):394-400.

Besta, F., Müller, I., M. Lorenz, M., Massberg, S., Bültmann, A.,

Cabeza, N., (2004). Reduced beta3-endonexin levels are associated with

enhanced urokinase-type plasminogen activator receptor expression in ApoE-

/- mice. Thromb Res., 114(4):283-92.

Blasi, F., Carmeliet, P. (2001). uPAR: a versatile signalling

orchestrator. Nat Rev Mol Cell Biol., 3(12):932-43.

Blasi, F., Sidenius, N. (2009). The urokinase receptor: focused cell

surface proteolysis, cell adhesion and signaling. FEBS Lett., 584(9):1923-30.

~ 52 ~

Børglum, A., Byskov, A., Ragno, P., Roldan, A., Tripputi, P., Cassani,

G., Danø, K. Blasi, F., Bolund, L., Kruse, T. (1992). Assignment of the

urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome

19q13.1-q13.2. Am J Hum Genet., 50(3):492-7.

Calin, G., Dumitru, C., Shimizu, M., Bichi, R., Zupo, S., Noch, E.,

Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M.,

Bullrich, F., Croce, C. (2002). Frequent deletions and down-regulation of

microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic

leukemia. Proc Natl Acad Sci U S A , 99(24):15524-9.

Campbell, P., Groehler, A., Lee, K., Ouellette, M., Khazak, V., Der, C.

(2007). K-Ras promotes growth transformation and invasion of immortalized

human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.

Cancer Res., 67(5):2098-106.

Carriero, M., Stoppelli, M. (2011). The urokinase-type plasminogen

activator and the generation of inhibitors of urokinase activity and signaling.

Curr Pharm Des., 17(19):1944-61.

Casey, J., Petranka, J., Kottra, J., Fleenor, D., Rosse, W. (1994). The

structure of the urokinase-type plasminogen activator receptor gene. Blood,

84(4):1151-6.

Cimmino, A., Calin, G., Fabbri, M., Iorio, M., Ferracin, M., Shimizu, M.,

Wojcik, S., Aqeilan, R., Zupo, S., Dono, M., Rassenti, L., Alder, H., Volinia, S.,

Liu, C., Kipps, T., Negrini, M., Croce, C. (2005). miR-15 and miR-16 induce

apoptosis by targeting BCL2. Proc Natl Acad Sci U S A., 102(39):13944-9.

Di Leva, G., Garofalo, M., Croce, C. (2014). MiRNA in cancer. Annu

Rev Pathol., 9:287-314.

Esquela-Kerscher, A., Slack, F. (2006). Oncomirs - miRNA with a role

in cancer. Nat Rev Cancer., 6(4):259-69.

Fang, Y., Sun, B., Li, Z., Chen, Z., Xiang, J. (2015). MiR-622 inhibited

colorectal cancer occurrence and metastasis by suppressing K-Ras. Mol

Carcinog., [Epub ahead of print].

Fibbi, G., Ziche, M., Morbidelli, L., Magnelli, L., Del Rosso, M. (1988).

Interaction of urokinase with specific receptors stimulates mobilization of

bovine adrenal capillary endothelial cells. Exp Cell Res., 179(2):385-95.

Furusato, B., Mohamed, A., Uhlén, M., Rhim, J. (2010). CXCR4 and

cancer. Pathol Int., 60(7):497-505.

BIBLIOGRAFIA

~ 53 ~

Gorrasi, A., Li Santi, A., Amodio, G., Alfano, D., Remondelli, P.,

Montuori, N., Ragno, P. (2014). The urokinase receptor takes control of cell

migration by recruiting integrins and FPR1 on the cell surface . PLoS One,

9(1):e86352.

Han, Z., Yang, Q., Liu, B., Wu, J., Li, Y., Yang, C., Jiang, Y. (2012).

MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and

enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis,

33(1):131-9.

Hapke, S., Kessler, H., Arroyo de Prada, N., Benge, A., Schmitt, M.,

Lengyel, E., Reuning, U. (2001). Integrin alpha(v)beta(3)/vitronectin

interaction affects expression of the urokinase system in human ovarian

cancer cells. J Biol Chem., 276(28):26340-8.

Hildenbrand, R., Gandhari, M., Stroebel, P., Marx, A., Allgayer, H.,

Arens, N. (2008). The urokinase-system-role of cell proliferation and

apoptosis. Histol Histopathol., 23(2):227-36.

Høyer-Hansen, G., Pessara, U., Holm, A., Pass, JU., Weidle,U., Danø, K.,

Behrendt, N. (1992) Urokinase plasminogen activator cleaves its cell surface

receptor releasing the ligand-binding domain. J Biol Chem., 267(25):18224-9.

Høyer-Hansen, G., Pessara, U., Holm, A., Pass, JU., Danø, K.,

Behrendt, N. (2001). Urokinase-catalysed cleavage of the urokinase receptor

requires an intact glycolipid anchor. Biochem J., 358(Pt 3):673-9.

Hwang, S., Seol, H., Park, Y., Kim, K., Gorospe, M., Nam, D., Kim, H.

(2012). MicroRNA-146a suppresses metastatic activity in brain metastasis.

Mol Cells, 34(3):329-34.

Irigoyen, J., Muñoz-Cánoves, P., Montero, L., Koziczak, M.,

Nagamine, Y. (1998). The plasminogen activator system: biology and

regulation. Cell Mol Life Sci., 56(1-2):104-32.

Kalyana-Sundaram, S., Kumar-Sinha, C., Shankar, S., Robinson, D.,

Wu, Y., Cao, X., Asangani, I., Kothari, V., Prensner, J., Lonigro, R., Iyer, M.,

Barrette, T., Shanmugam, A., Dhanasekaran, S., Palanisamy, N., Chinnaiyan,

A. (2012). Expressed pseudogenes in the transcriptional landscape of human

cancers. Cell, 149(7):1622-34.

Karreth, F. R., Ruocco, A., C, N., Chapuy, B., Léopold, V., Sjoberg,

M., Verma, KTA., Ala, U., Tay, Y., Wu, D., Seitzer, N., Velasco-Herrera Mdel,

C., Bothmer, A., Fung, J., Langellotto, F., Rodig, SJ., Elemento, O., Shipp,

MA., Adams, DJ., Charlie, R., Pandolfi, PP. (2015). The BRAF pseudogene

~ 54 ~

functions as a competitive endogenous RNA and induces lymphoma in vivo.

Cell, 161(2):319-32.

Keene, J. (2010). The global dynamics of RNA stability orchestrates

responses to cellular activation. BMC Biol., 8:95.

Khabar, K. (2010). Post-transcriptional control during chronic

inflammation and cancer: a focus on AU-rich elements . Cell Mol Life Sci.,

67(17):2937-55.

Kirchheimer, J., Wojta, J., Christ, G., Binder, B. (1989). Functional

inhibition of endogenously produced urokinase decreases cell proliferation in

a human melanoma cell line. Proc Natl Acad Sci U S A, 86(14):5424-8.

Kjaergaard, M., Hansen, L., Jacobsen, B., Gardsvol, H., Ploug, M.

(2008). Structure and ligand interactions of the urokinase receptor (uPAR) .

Front Biosci., 13:5441-61.

Kjøller, L., Hall, A. (2001). Rac mediates cytoskeletal rearrangements

and increased cell motility induced by urokinase-type plasminogen activator

receptor binding to vitronectin. J Cell Biol., 152(6):1145-57.

Kolenda, T., Przybyła, W., Teresiak, A., Mackiewicz, A., Lamperska,

K. (2014). The mystery of let-7d - a small RNA with great power. Contemp

Oncol (Pozn)., 18(5):293-301.

Kumar, MS, Armenteros-Monterroso, E., East, P., Chakravorty, P.,

Matthews, N., Winslow, M., Downward, J. (2014). HMGA2 functions as a

competing endogenous RNA to promote lung cancer progression. Nature,

505(7482):212-7.

Labbaye, C., Testa, U. (2012). The emerging role of MIR-146A in the

control of hematopoiesis, immune function and cancer. J Hematol Oncol.,

5:13.

Labbaye, C., Spinello, I., Quaranta, M., Pelosi, E., Pasquini, L.,

Petrucci, E., Biffoni, M., Nuzzolo, E., Billi, M., Foà, R., Brunetti, E., Grignani,

F., Testa, U., Peschle, C. (2008). A three-step pathway comprising

PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol., 10(7):788-

801.

Lanza, F., Castoldi, G., Castagnari, B., Todd, R., Moretti, S., Spisani,

S., Latorraca, A., Focarile, E., Roberti, M., Traniello, S. (1998). Expression

and functional role of urokinase-type plasminogen activator receptor in normal

and acute leukaemic cells. Br J Haematol., 103(1):110-23.

BIBLIOGRAFIA

~ 55 ~

Lee, BM., Gusev, Y., Brackett, D., Nuovo, G., Schmittgen, T. (2008).

Systematic evaluation of microRNA processing patterns in tissues, cell lines,

and tumors. RNA, 14(1):35-42.

Liu, H., Li, W., Chen, C., Pei, Y., Long, X. (2015). MiR-335 acts as a

potential tumor suppressor miRNA via downregulating ROCK1 expression in

hepatocellular carcinoma. Tumour Biol., 36(8):6313-9.

Lund, L., Ellis, V., Rønne, E., Pyke, C., Danø, K. (1995).

Transcriptional and post-transcriptional regulation of the receptor for

urokinase-type plasminogen activator by cytokines and tumour promoters in

the human lung carcinoma cell line A549 . Biochem J., 310 ( pt1 ): 345-52.

Markiewicz, A., Książkiewicz, M., Wełnicka-Jaśkiewicz, M.,

Seroczyńska, B., Skokowski, J., Szade, J., Żaczek, A.J., (2014).

Mesenchymal phenotype of CTC-enriched blood fraction and lymphnode

metastasis formation potentia. PLoS One, 9(4):e93901.

Mongroo, P., Rustgi, A. (2010). The role of the miR-200 family in

epithelial-mesenchymal transition. Cancer Biol Ther., 10(3):219-22. .

Montuori, N., Ragno, P. (2009). «Multiple activities of a multifaceted

receptor: roles of cleaved and soluble uPAR. Front Biosci. (Landmark Ed),

14:2494-503.

Montuori, N., Carriero, M., Salzano, S., Rossi, G., Ragno, P. (2002).

The cleavage of the urokinase receptor regulates its multiple functions. J Biol

Chem., 277(49):46932-9.

Montuori, N., Cosimato, V., Rinaldi, L., Rea, V., Alfano, D., Ragno, P.

(2013). uPAR regulates pericellular proteolysis through a mechanism

involving integrins and fMLF-receptors. Thromb Haemost., 109(2):309-18.

Montuori, N., Mattiello, A., Mancini, A., Taglialatela, P., Caputi, M.,

Rossi, G., Ragno, P. (2003). Urokinase-mediated posttranscriptional

regulation of urokinase-receptor expression in non small cell lung carcinoma.

Int J Cancer, 105(3):353-60.

Nagamine, Y., Medcalf, R., Muñoz-Cánoves, P. (2005). Transcriptional

and posttranscriptional regulation of the plasminogen activator system.

Thromb Haemost., 93(4):661-75.

Noh, H., Hong, S., Huang, S. (2013). Role of urokinase receptor in

tumor progression and development. Theranostics., 3(7):487-95.

O'Day, E., Lal, A. (2010). MiRNA and their target gene networks in

breast cancer. Breast Cancer Res., 12(2):201.

~ 56 ~

Ploug, M., Eriksen, J., Plesner, T., Hansen, N., Dako, K. (1992). A

soluble form of the glycolipid-anchored receptor for urokinase-type

plasminogen activator is secreted from peripheral blood leukocytes from

patients with paroxysmal nocturnal hemoglobinuria. Eur J. Biochem.,

208(2):397-404.

Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W.,

Pandolfi, PP.(2010). A coding-independent function of gene and pseudogene

mRNAs regulates tumour biology. Nature., 465(7301):1033-8.

Ragno, P. (2006). The urokinase receptor: a ligand or a receptor?

Story of a sociable molecule. Cell Mol Life Sci., 63(9):1028-37.

Rath, N., Olson, M. (2012). Rho-associated kinases in tumorigenesis:

re-considering ROCK inhibition for cancer therapy. EMBO Rep., 13(10):900-8.

Resnati, M., Pallavicini, I., Wang, J., Oppenheim, J., Serhan, C.,

Romano, M., Blasi, F. (2002). The fibrinolytic receptor for urokinase activates

the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad

Sci U S A., 5;99(3):1359-64.

Rijken, D. Lijnen, H. (2009). New insights into the molecular

mechanisms of the fibrinolytic system. J Thromb Haemost., 7(1):4-13.

Sand, L., Jochemsen, A., Beletkaia, E., Schmidt, T., Hogendoorn, P.,

Szuhai, K. (2015). Novel splice variants of CXCR4 identified by transcriptome

sequencing. Biochem Biophys Res Commun., 466(1):89-94.

Shenouda, S., Alahari, S. (2009). MicroRNA function in cancer:

oncogene or a tumor suppressor? Cancer Metastasis Rev., 28(3-4):369-78.

Shetty,S., Muniyappa, H., Halady P.K., Idell S. (2004). Regulation of

urokinase receptor expression by phosphoglycerate kinase. Am J Respir Cell

Mol Biol., 31(1):100-6.

Shetty, S., Velusamy, T., Idell, S., Shetty, P., Mazar, A., Bhandary, Y.,

Shetty, R. (2007). Regulation of urokinase receptor expression by p53: novel

role in stabilization of uPAR mRNA. Mol Cell Biol., 27(16):5607-18.

Shetty, P., Velusamy, T., Bhandary, Y., Shetty, R., Liu, M., Shetty, S.

(2008). Urokinase expression by tumor suppressor protein p53: a novel role in

mRNA turnover. Am J Respir Cell Mol Biol., 39(3):364-72.

Shetty, P., Velusamy, T., Bhandary, Y., Liu, M., Shetty, S. (2009).

Urokinase receptor expression involves tyrosine phosphorylation of

phosphoglycerate kinase. Mol Cell Biochem., 335(1-2):235-47.

BIBLIOGRAFIA

~ 57 ~

Shetty, S., Marudamuthu, A., Abernathy, D., Shetty, R., Shetty, P., Fu,

J., Idell, S., Bhandary, Y., Ji, H., Liu, M., Shetty, S. (2012). Regulation of

urokinase expression at the posttranscription level by lung epithelial cells.

Biochemistry., 51(1):205-13.

Sidenius, N., Blasi, F. (2003). The urokinase plasminogen activator

system in cancer: recent advances and implication for prognosis and therapy.

Cancer Metastasis Rev., 22(2-3):205-22.

Silva, H., Alves, V., Nogueira, L., Rosa, M., Carvalho, L., Regateiro, F.

(2012). Impairment of breast cancer cell invasion by COX-2-specific inhibitor

NS398: roles of CXCR4 and of uPA system. Med Oncol., 29(3):1468-76.

Stewart, C., Sayers, I. (2009). Characterisation of urokinase

plasminogen activator receptor variants in human airway and peripheral cells.

BMC Mol Biol., 10:75.

Tang, C., Hill, M., Brumwell, A., Chapman, H., Wei, Y. (2008).

Signaling through urokinase and urokinase receptor in lung cancer cells

requires interactions with beta1 integrins. J Cell Sci., 121(Pt 22):3747-56.

Tarighi, P., Montazeri, H., Khorramizadeh, M., Sobhani, A., Ostad, S.,

Ghahremani, M. (2015). uPAR peptide antagonist alters regulation of MAP

kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell

line. Res Pharm Sci., 10(3):200-5.

Tay, Y., Karreth, F., Pandolfi, PP. (2014). Aberrant ceRNA activity

drives lung cancer. Cell Res., 24(3):259-60. .

Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S., Ala, U., Karreth, F. ,

Poliseno, L., Provero, P., Di Cunto, F., Lieberman, J., Rigoutsos, I., Pandolfi,

PP. (2011). Coding-independent regulation of the tumor suppressor PTEN by

competing endogenous mRNAs. Cell., 147(2):344-57.

Teicher, B., Fricker, S. (2010). CXCL12 (SDF-1)/CXCR4 pathway in

cancer. Clin Cancer Res., 16(11):2927-31.

Tran, H., Maurer, F., Nagamine, Y. (2003). Stabilization of urokinase

and urokinase receptor mRNAs by HuR is linked to its cytoplasmic

accumulation induced by activated mitogen-activated protein kinase-activated

protein kinase 2. Mol Cell Biol., 23(20):7177-88.

Trisciuoglio, D., Iervolino, A., Candiloro, A., Fibbi, G., Fanciulli, M.,

Zangemeister-Wittke, U., (2004). bcl-2 induction of urokinase plasminogen

activator receptor expression in human cancer cells through Sp1 activation:

involvement of ERK1/ERK2 activity. J Biol Chem., 279(8):6737-45.

~ 58 ~

Volinia, S., Calin, G., Liu, C., Ambs, S., Cimmino, A., Petrocca, F.,

Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R., Yanaihara, N.,

Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris C., Croce, C.,

(2006). A microRNA expression signature of human solid tumors defines

cancer gene targets. Proc Natl Acad Sci U S A, 103(7):2257-61.

Wang, X., Tang, S., Le, S., Lu, R., Rader, J., Meyers, C., Zheng, Z.

(2008). Aberrant expression of oncogenic and tumor-suppressive miRNA in

cervical cancer is required for cancer cell growth. PLoS One., 3(7):e2557.

Wang, Y., Dang, J., Johnson, L., Selhamer, J., Doe, W. (1995).

Structure of the human urokinase receptor gene and its similarity to CD59 and

the Ly-6 family. Eur J Biochem., 227(1-2):116-22.

Wang, Y., Zhao, W., Fu, Q. (2013). miR-335 suppresses migration and

invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem.,

384(1-2):105-11.

Yu, M., Wang, J., Wang, G., You, X., Zhao, X., Jing, Q., Qin, Y.

(2011). Vascular smooth muscle cell proliferation is influenced by let-7d

microRNA and its interaction with KRAS. Circ J., 75(3):703-9.

Zannetti, A., Del Vecchio, S., Carriero, M., .Fonti, R., Franco, P., Botti,

G., D'Aiuto, G., Stoppelli, M., Salvatore, M. (2000). Coordinate up-regulation

of Sp1 DNA-binding activity and urokinase receptor expression in breast

carcinoma. Cancer Res., 60(6):1546-51.

Zhang, B., Pan, X., Cobb, G. P, Anderson, T.A. (2007). miRNA as

oncogenes and tumor suppressors. Dev Biol., 302(1):1-12.

Nel documento Regolazione post-trascrizionale dell’espressione del recettore dell’urochinasi (pagine 54-62)